Clinical Trials Logo

Shock, Septic clinical trials

View clinical trials related to Shock, Septic.

Filter by:

NCT ID: NCT02899702 Withdrawn - Clinical trials for Staphylococcal Infection

Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children

IGHN2
Start date: September 2020
Phase: Phase 4
Study type: Interventional

IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment in the acute phase of streptococcal or staphylococcal toxic shock syndrome in children.

NCT ID: NCT02885688 Withdrawn - Septic Shock Clinical Trials

Early Metabolic Support as a Potential Solution to Multi-Organ Dysfunction Syndrome (MODS) During Severe Sepsis

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if adding liquid nutrition therapy that is given by vein to standard-of-care treatment for sepsis can help to control sepsis symptoms better than giving standard-of-care treatment alone. Researchers also want to compare the length of ICU and hospital stay and any side effects between these 2 treatments.

NCT ID: NCT02771158 Withdrawn - Sepsis Clinical Trials

Midodrine During Recovery From Septic Shock

Start date: August 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.

NCT ID: NCT02699905 Withdrawn - Sepsis Clinical Trials

Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis

GPR43Sepsis
Start date: August 2016
Phase: N/A
Study type: Observational

This study seeks to elucidate the quantitative expression of G - protein receptor 43/free fatty acid (GPR43/FFA2) receptors in patients with the diagnosis of sepsis and specifically, its expression as it relates to the severity of sepsis. The investigators hypothesize that patients with more severe sepsis, as defined by a higher SOFA (Sequential Organ Failure Assessment Score), will have decreased expression of the GPR43/FFA2 as compared to patients with lower SOFA scores, consistent with a less exuberant immune response to infection. Patients admitted to Penn State Hershey Medical Center with a diagnosis of sepsis of any cause will undergo blood testing of leukocytes to determine the expressed quantity of GP43 during standardized time points of their illness and recovery. No interventions will be made in the standard clinical management of the patient. Additionally, healthy volunteers will be recruited to exam baseline GPR43 receptor expression between sepsis and control groups.

NCT ID: NCT02609152 Withdrawn - Shock, Septic Clinical Trials

Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock

BétaSep
Start date: July 2016
Phase: Phase 3
Study type: Interventional

The main objective of this study is to evaluate the effectiveness of the administration of a short acting beta-blocker in terms of effective increase in stroke volume (at least 15%) after 4 hours initiation of therapy in septic shock in patients with a hyperkinetic profile after 12-24 hours of care. This research seeks to demonstrate that the proportion of patients with an increase in the systolic ejection superior or equal to 15% (relative to baseline) at four hours is different between the two arms of the study: (1) an experimental arm where patients receive an esmolol infusion according to a predetermined procedure and (2) a control arm where patients receive a saline infusion according to a predetermined procedure.

NCT ID: NCT02454348 Withdrawn - Shock, Septic Clinical Trials

NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock

NOVEL
Start date: November 1, 2015
Phase: Phase 4
Study type: Interventional

Sepsis, a systemic host response to the invasion of a pathogenic microorganism, may progress to severe sepsis, wherein the patient experiences acute dysfunction in at least one organ system, and further develop into septic shock if the patient cannot regain adequate systemic blood pressure and perfusion after adequate and appropriate fluid resuscitation. Further prospective study of the potential mortality benefit with combination norepinephrine and vasopressin in critically ill patients with septic shock needs to be performed. Our research will resolve this essential question and improve the scientific knowledge surrounding vasoactive medications in patients with septic shock.

NCT ID: NCT02277977 Withdrawn - Sepsis Clinical Trials

Evaluation of Impaired Microcirculation During Septic Shock With Contrast Enhanced Ultrasound

Start date: November 2014
Phase: N/A
Study type: Interventional

Microcirculatory disorders play a central role in the pathogenesis of sepsis and septic shock. Without adequate therapy that may lead to multi-organ failure and death. Therefore useful therapeutic measures aim to improve the microcirculation, to avoid tissue hypoxia and thus multiple organ failure or death. Clinically, the microcirculation can currently be indirectly evaluated using the diuresis and metabolic parameters (eg, lactate). The aim of the present study is to measure the microcirculation in septic shock by means of contrast-enhanced sonography of the calf muscles. For this purpose, the method is applied to 24 subjects during and after septic shock. It will be investigated in this study whether the microcirculation measurement with ultrasound contrast reflects the severity of the disease. As well as to evaluate whether the use of this diagnostic method could lead to better treatment of the septic shock.

NCT ID: NCT02069288 Withdrawn - Septic Shock Clinical Trials

Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock

FLUDRO
Start date: n/a
Phase: Phase 3
Study type: Interventional

Septic shock (associated with relative adrenal insufficiency) is characterized by decreased arterial responsiveness to catecholamines. The association of hydrocortisone and fludrocortisone has demonstrated an improvement in survival in septic shock patients. If hydrocortisone has shown to increase vascular responsiveness, the role of fludrocortisone remains to be elucidated. The purpose of our study is to investigate the effect of a physiological dose of fludrocortisone alone on norepinephrine-mean arterial pressure dose-response relationship, gastric mucosal perfusion and arterial stiffness in patients with septic shock.

NCT ID: NCT01926301 Withdrawn - Septic Shock Clinical Trials

Cerebrovascular Autoregulation in Sepsis, Influence of Renal Replacement Therapy

SepsAR2
Start date: August 2013
Phase:
Study type: Observational

The cerebrovascular autoregulation is impaired in patients with severe sepsis and septic shock. A continuous veno-venous hemodialysis may improve impaired cerebrovascular autoregulation. Hypothesis: continuous hemodialysis recovers impaired cerebrovascular autoregulation in patients with acute severe sepsis and septic shock.

NCT ID: NCT01601938 Withdrawn - Sepsis Clinical Trials

Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients

SEREAL
Start date: September 2012
Phase: Phase 2
Study type: Interventional

This study will be performed to determine whether selenium replacement reduces 28-day mortality of severe sepsis and septic shock patients, and to investigate whether selenium replacement contributes differently to the mortality reduction of the patients according to their initial serum selenium level.